Posted today, 4hrs ago.
Following the upgrade, the current consensus from Zoono Group’s sole analyst is for revenues of NZ$38m in 2020 which – if met – would reflect a substantial increase on its sales over the past 12 months. The losses are expected to disappear over the next year or so, with forecasts for a profit of NZ$0.067 per share this year. Previously, the analyst had been modelling revenues of NZ$25m and earnings per share (EPS) of NZ$0.044 in 2020. So we can see there’s been a pretty clear increase in analyst sentiment in recent times, with both revenues and earnings per share receiving a decent lift in the latest estimates.
It will come as no surprise to learn that the analyst has increased their price target for Zoono Group 12% to NZ$3.88 on the back of these upgrades.
https://**.st/stocks/au/materials/asx-zno/zoono-group-shares/news/zoono-group-limiteds-asxzno-sole-analyst-just-made-a-huge-upgrade-to-their-forecasts/
Big news
- Forums
- ASX - By Stock
- ZNO
- Zoono given a price target of 3.65
ZNO
zoono group limited
Add to My Watchlist
0.00%
!
3.2¢

Zoono given a price target of 3.65
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
|
|||||
Last
3.2¢ |
Change
0.000(0.00%) |
Mkt cap ! $11.37M |
Open | High | Low | Value | Volume |
3.2¢ | 3.2¢ | 3.2¢ | $975 | 30.45K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 375795 | 3.2¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
3.4¢ | 29854 | 2 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 375795 | 0.032 |
1 | 31833 | 0.031 |
3 | 213910 | 0.030 |
3 | 79482 | 0.029 |
7 | 292434 | 0.028 |
Price($) | Vol. | No. |
---|---|---|
0.034 | 4854 | 1 |
0.036 | 400000 | 1 |
0.037 | 307528 | 1 |
0.040 | 139733 | 3 |
0.060 | 327865 | 4 |
Last trade - 15.59pm 04/07/2025 (20 minute delay) ? |
Featured News
ZNO (ASX) Chart |
The Watchlist
NUZ
NEURIZON THERAPEUTICS LIMITED
Dr Michael Thurn, CEO & MD
Dr Michael Thurn
CEO & MD
SPONSORED BY The Market Online